Stockreport
NTLA Stock Rises 20% in 3 Months: Here's What You Should Know [Yahoo! Finance]
Last regeneron pharmaceuticals, inc. earnings: 2/6 06:30 am
Check Earnings Report
US:NASDAQ Investor Relations: investor.regeneron.com
The encouraging clinical progress with its pipeline candidates likely raised investor optimism, resulting in the stock's rise during this period. Intellia's top line currently consists primarily of collaboration revenues from partners such as Regeneron Pharmaceuticals REGN and others. These partnerships are beneficial, enabling Intellia to leverage external capabilities and resources to advance its therapeutic development programs. NTLA's Recent Pipeline Updates Intellia has collaborated with Regeneron for the development of its investigational in vivo genome-editing candidate, nexiguran ziclumeran (nex-z), which is being studied for two indications — ATTR amyloidosis with polyneuropathy (ATTRv-PN) and ATTR amyloidosis with cardiomyopathy (ATTR-CM). Last month, the FDA lifted the clinical hold on the investigational new drug application (IND) for the phase III MAGNITUDE study evaluating nex-z in patients with ATTR-CM. Earlier this year, the FDA lifted the clinical hold on th
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | REGN | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
REGN alerts
REGN alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
REGN alerts
High impacting Regeneron Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
REGN
NEWS
NEWS
- Why Telix Pharmaceuticals (ASX:TLX) Is Up 13.8% After Regeneron Radiopharma Alliance Announcement And What's Next [Yahoo! Finance][Yahoo! Finance]
- Regeneron and Telix Announce Strategic Radiopharma Collaboration[GlobeNewswire]
- Dupixent® (dupilumab) Approved in the EU as the First Targeted Medicine to Treat Young Children with Chronic Spontaneous Urticaria (CSU)[GlobeNewswire]
- Telix and Regeneron Announce Strategic Radiopharma Collaboration[PR Newswire]
- Regeneron Pharmaceuticals (REGN) had its price target raised by Morgan Stanley from $769.00 to $796.00. They now have an "equal weight" rating on the stock.[MarketBeat]
- More
REGN
SEC Filings
SEC Filings
- 4/8/26 - Form 8-K
- 4/3/26 - Form 4
- 3/27/26 - Form SCHEDULE
- REGN's page on the SEC website
- More